{"filing":{"accession_number":"0001193125-26-403424","cik":"0001650648","ticker":"FDMT","company_name":"4D Molecular Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"d147828d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526403424/d147828d8k.htm"},"events":[{"id":35320,"run_id":32528,"accession_number":"0001193125-26-403424","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure reports enrollment of first patients in the Phase 3 4SIGHT clinical trial for 4D-150 in diabetic macular edema and release of 2-year SPECTRA trial data showing favorable safety and efficacy results. This is a material clinical development milestone for a biopharmaceutical company's lead product candidate, demonstrating progress toward regulatory approval and commercialization. The event is operational/strategic in nature—a significant clinical advancement—rather than fitting a specific financial, governance, or legal category.","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39334,"accession_number":"0001193125-26-403424","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports enrollment of first patients in the Phase 3 4SIGHT clinical trial for 4D-150 in diabetic macular edema and release of 2-year SPECTRA trial data showing favorable safety and efficacy results. This is a material clinical development milestone for a biopharmaceutical company's lead product candidate, demonstrating progress toward regulatory approval and commercialization. The event is operational/strategic in nature—a significant clinical advancement—rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:08:18.955891+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39334,"accession_number":"0001193125-26-403424","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports enrollment of first patients in the Phase 3 4SIGHT clinical trial for 4D-150 in diabetic macular edema and release of 2-year SPECTRA trial data showing favorable safety and efficacy results. This is a material clinical development milestone for a biopharmaceutical company's lead product candidate, demonstrating progress toward regulatory approval and commercialization. The event is operational/strategic in nature—a significant clinical advancement—rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:08:18.955891+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-09-28"}]}